FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034483268> ?p ?o ?g. }

• W2034483268 endingPage "91" @default.
• W2034483268 startingPage "85" @default.
• W2034483268 abstract "Summary Background Improvements in knowledge of molecular mechanisms in cancer are the basis for new studies combining chemotherapy with targeted drugs. Inhibition of the epidermal growth factor receptor (EGFR) by erlotinib or cetuximab has limited or no activity, respectively, in pancreatic cancer. The crosstalk between EGFR and mammalian target of rapamycin (mTOR) pathways is a potential mechanism of resistance; therefore we conducted a study to explore safety and efficacy of multiple pathway inhibition by cetuximab and everolimus in combination with capecitabine. Methods Safety and efficacy of fixed standard dose cetuximab in combination with various dose levels of everolimus (5–10 mg/day) and capecitabine (600–800 mg/m 2 bid, 2 weeks every 3 weeks) were investigated in a phase I/II study in patients with advanced pancreatic cancer. The primary endpoint was objective response. Results Sixteen patients were treated in the phase I part at two dose levels. Mucositis, rash and hand-foot syndrome were dose-limiting toxicities. Dose level 1 (everolimus 5 mg/day, capecitabine 600 mg/m 2 bid for 2 weeks every 3 weeks and cetuximab 250 mg/m 2 weekly) was considered the maximum tolerated dose (MTD). Of 31 patients in the phase II part, partial response was documented in two patients (6.5%) and five (16.1%) had stable disease. Median overall survival was 5.0 months (CI 3.1–6.8). Conclusion The schedule of capecitabine, everolimus and cetuximab resulted in considerable epidermal and mucosal toxicities and prevented escalation to optimal dose levels. Because of toxicity and low efficacy this treatment combination cannot be recommended for treatment in pancreatic cancer patients." @default.
• W2034483268 created "2016-06-24" @default.
• W2034483268 creator A5020475778 @default.
• W2034483268 creator A5037240605 @default.
• W2034483268 creator A5044963215 @default.
• W2034483268 creator A5052741985 @default.
• W2034483268 creator A5078986987 @default.
• W2034483268 creator A5089069968 @default.
• W2034483268 date "2012-02-25" @default.
• W2034483268 modified "2023-10-07" @default.
• W2034483268 title "A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer" @default.
• W2034483268 cites W1931508686 @default.
• W2034483268 cites W1987757716 @default.
• W2034483268 cites W2024086004 @default.
• W2034483268 cites W2038598054 @default.
• W2034483268 cites W2041234310 @default.
• W2034483268 cites W2059890247 @default.
• W2034483268 cites W2068672560 @default.
• W2034483268 cites W2073865770 @default.
• W2034483268 cites W2074496248 @default.
• W2034483268 cites W2099023480 @default.
• W2034483268 cites W2103885687 @default.
• W2034483268 cites W2111065680 @default.
• W2034483268 cites W2115499099 @default.
• W2034483268 cites W2115686439 @default.
• W2034483268 cites W2118677643 @default.
• W2034483268 cites W2125129553 @default.
• W2034483268 cites W2128259734 @default.
• W2034483268 cites W2129931005 @default.
• W2034483268 cites W2138297714 @default.
• W2034483268 cites W2141448895 @default.
• W2034483268 cites W2144025124 @default.
• W2034483268 cites W2145616602 @default.
• W2034483268 cites W2147483024 @default.
• W2034483268 cites W2149218373 @default.
• W2034483268 cites W2151253787 @default.
• W2034483268 cites W2154108823 @default.
• W2034483268 cites W2158134441 @default.
• W2034483268 cites W2158734599 @default.
• W2034483268 cites W2160565595 @default.
• W2034483268 cites W2161764875 @default.
• W2034483268 cites W4213229297 @default.
• W2034483268 doi "https://doi.org/10.1007/s10637-012-9802-1" @default.
• W2034483268 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3553409" @default.
• W2034483268 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22367239" @default.
• W2034483268 hasPublicationYear "2012" @default.
• W2034483268 type Work @default.
• W2034483268 sameAs 2034483268 @default.
• W2034483268 citedByCount "28" @default.
• W2034483268 countsByYear W20344832682013 @default.
• W2034483268 countsByYear W20344832682014 @default.
• W2034483268 countsByYear W20344832682015 @default.
• W2034483268 countsByYear W20344832682016 @default.
• W2034483268 countsByYear W20344832682017 @default.
• W2034483268 countsByYear W20344832682018 @default.
• W2034483268 countsByYear W20344832682019 @default.
• W2034483268 countsByYear W20344832682020 @default.
• W2034483268 countsByYear W20344832682021 @default.
• W2034483268 countsByYear W20344832682022 @default.
• W2034483268 countsByYear W20344832682023 @default.
• W2034483268 crossrefType "journal-article" @default.
• W2034483268 hasAuthorship W2034483268A5020475778 @default.
• W2034483268 hasAuthorship W2034483268A5037240605 @default.
• W2034483268 hasAuthorship W2034483268A5044963215 @default.
• W2034483268 hasAuthorship W2034483268A5052741985 @default.
• W2034483268 hasAuthorship W2034483268A5078986987 @default.
• W2034483268 hasAuthorship W2034483268A5089069968 @default.
• W2034483268 hasBestOaLocation W20344832681 @default.
• W2034483268 hasConcept C121608353 @default.
• W2034483268 hasConcept C126322002 @default.
• W2034483268 hasConcept C143998085 @default.
• W2034483268 hasConcept C203092338 @default.
• W2034483268 hasConcept C2776694085 @default.
• W2034483268 hasConcept C2777909004 @default.
• W2034483268 hasConcept C2778087573 @default.
• W2034483268 hasConcept C2778496288 @default.
• W2034483268 hasConcept C2778570526 @default.
• W2034483268 hasConcept C2779438470 @default.
• W2034483268 hasConcept C2779699572 @default.
• W2034483268 hasConcept C2779998722 @default.
• W2034483268 hasConcept C2780210213 @default.
• W2034483268 hasConcept C31760486 @default.
• W2034483268 hasConcept C526805850 @default.
• W2034483268 hasConcept C535046627 @default.
• W2034483268 hasConcept C71924100 @default.
• W2034483268 hasConcept C98274493 @default.
• W2034483268 hasConceptScore W2034483268C121608353 @default.
• W2034483268 hasConceptScore W2034483268C126322002 @default.
• W2034483268 hasConceptScore W2034483268C143998085 @default.
• W2034483268 hasConceptScore W2034483268C203092338 @default.
• W2034483268 hasConceptScore W2034483268C2776694085 @default.
• W2034483268 hasConceptScore W2034483268C2777909004 @default.
• W2034483268 hasConceptScore W2034483268C2778087573 @default.
• W2034483268 hasConceptScore W2034483268C2778496288 @default.
• W2034483268 hasConceptScore W2034483268C2778570526 @default.
• W2034483268 hasConceptScore W2034483268C2779438470 @default.
• W2034483268 hasConceptScore W2034483268C2779699572 @default.
• W2034483268 hasConceptScore W2034483268C2779998722 @default.

• next